Quick Answer
Bionano Genomics, Inc. reported Diluted EPS of $4.85 per share (loss) for fiscal year 2025.
Bionano Genomics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$4.85 | +94.5% |
| 2024 | -$88.13 | +78.4% |
| 2023 | -$408.60 | -8821.4% |
| 2022 | -$4.58 | -1661.5% |
| 2021 | -$0.26 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.59 | +94.9% | +20.1% |
| June 30, 2025 | -$1.99 | +86.2% | -73.0% |
| March 31, 2025 | -$1.15 | +96.8% | +96.3% |
| September 30, 2024 | -$30.92 | -860.2% | -114.6% |
| June 30, 2024 | -$14.41 | -1062.1% | +59.7% |
| March 31, 2024 | -$35.75 | -2806.5% | -1010.2% |
| September 30, 2023 | -$3.22 | -192.7% | -159.7% |
| June 30, 2023 | -$1.24 | -9.7% | -0.8% |
- Bionano Genomics, Inc. showed an increase of +94.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Bionano Genomics, Inc.’s diluted eps has declined by 1765.4% (from $0.26 per share (loss) to $4.85 per share (loss)).
- The most recent figure is from Bionano Genomics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: